eFFECTOR Therapeutics Inc

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Solana Beach, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

- Key executive appointments: Douglas Warner, M.D., as CMO & Mayank Gandhi, M.D., as CBO –

eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Topline data, including safety and viral load reduction results from all three cohorts anticipated in the first half of 2023 Topline data, including safety and viral load reduction results from all three cohorts anticipated in the first half of 2023

eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has appointed Mayank J. Gandhi, M.D., as chief business officer. Dr. Gandhi will lead eFFECTOR's corporate growth strategy, business development and partnership opportunities.

eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

- Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET - - Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET -

eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference

- Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 -

eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

SAN DIEGO and REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the upcoming H.C. Wainwright 24 th Annual Global Investment Conference.

eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial

eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has appointed Douglas Warner, M.D., as chief medical officer. Dr. Warner will develop strategies to continue advancing eFFECTOR's two clinical-stage STRIs into advanced and potentially registrational trials.

eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer

Nexgel

Invacare

TRACON Pharmaceuticals

U.S. crude oil futures traded higher by over 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades.

4 Stocks Under $2 Insiders Are Aggressively Buying: NEXGEL, eFFECTOR Therapeutics And More

Two partial responses observed in heavily pre-treated ER+ breast cancer patients

eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity

Positive initial data demonstrated pharmacologically relevant exposures

eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting

Plan to present data at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial

eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Premal Patel, M.D., Ph.D., chief medical officer, has resigned to pursue a new career opportunity

eFFECTOR Therapeutics Announces Transition in Clinical Leadership

SAN DIEGO and REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update.

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

SAN DIEGO and REDWOOD CITY, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Kristen Harrington-Smith, Senior Vice President & Chief Commercial Officer at ImmunoGen, to the company's board of directors. Concurrent with Ms. Harrington-Smith's appointment, Jonathan Root, M.D., has resigned from the company's board of directors.

eFFECTOR Appoints Kristen Harrington-Smith to Board of Directors

SAN DIEGO and REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the 2022 BIO CEO & Investor Conference.

eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor Conference

Tomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) evaluating frontline maintenance in PD-L1 ≥1% patient population, representing additional $5 billion U.S. market opportunity

eFFECTOR Therapeutics Provides Pipeline and Business Updates

Study Demonstrates Role of Zotatifin in Blocking Tumor Growth in Receptor Tyrosine Kinase Driven Tumors Study Demonstrates Role of Zotatifin in Blocking Tumor Growth in Receptor Tyrosine Kinase Driven Tumors

eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that Steve Worland, Ph.D., President and Chief Executive Officer of eFFECTOR, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Monday, December 6 at 3:20 p.m. ET.

eFFECTOR Therapeutics to Participate in The JMP Securities Hematology and Oncology Summit

•   Continuing to enroll patients in Phase 2b KICKSTART study of tomivosertib in combination with pembrolizumab, a U.S. Food and Drug Administration (FDA) approved PD-1 inhibitor

eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Barbara Klencke, M.D., Chief Medical Officer and Chief Development Officer at Sierra Oncology, to the company's board of directors. Concurrent with Dr. Klencke's appointment, Larry Lasky, Ph.D., has resigned from the company's board of directors.

eFFECTOR Appoints Barbara Klencke, M.D., to Board of Directors

The stock price of eFFECTOR Therapeutics (NASDAQ: EFTR) increased by 25% during intraday trading. This is why it happened.

EFTR Stock: Why It Increased By 25% Today

eFFECTOR Therapeutics Inc (NASDAQ: EFTR), in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zotatifin in animal models of triple-negative breast cancer (TNBC). The data were at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

eFFECTOR Therapeutics Stock Gains On Encouraging Preclinical Zotatifin Data In Breast Cancer

• Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem-cell signaling pathways

Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that eFFECTOR-supported research from Baylor College of Medicine entitled, “The RNA helicase EIF4A is a therapeutic vulnerability in triple-negative breast cancer” has been accepted as a poster presentation at the upcoming 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

News for eFFECTOR Therapeutics Inc Stock (EFTR)